A Novel Transgenic Mouse Model Implicates Sirt2 as a Promoter of Hepatocellular Carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths globally. Incidence rates are steadily increasing, creating an unmet need for new therapeutic options. Recently, the inhibition of sirtuin-2 (Sirt2) was proposed as a potential treatment for HCC, despite contradictory findings of its role as both a tumor promoter and suppressor in vitro. Sirt2 functions as a lysine deacetylase enzyme. However, little is known about its biological influence, despite its implication in several age-related diseases. This study evaluated Sirt2's role in HCC in vivo using an inducible c-MYC transgene in Sirt2^+/+ and Sirt2^-/- mice. Sirt2^-/- HCC mice had smaller, less proliferative, and mo

SUBMITTER: Schmidt AV 

PROVIDER: S-EPMC10454864 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature